Cyclophosphamide and Alemtuzumab In Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 30, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions
Non Hodgkin LymphomaHigh-grade B-cell LymphomaDiffuse Large B Cell Lymphoma
Interventions
DRUG

Cyclophosphamide

"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~\- Via IV Day 3"

DRUG

Alemtuzumab

"* The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~ * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4"

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03132584 - Cyclophosphamide and Alemtuzumab In Lymphoma | Biotech Hunter | Biotech Hunter